A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
Status:
Recruiting
Trial end date:
2031-09-01
Target enrollment:
Participant gender:
Summary
This is a clinical trial to evaluate the feasibility and safety of giving tazemetostat
followed by standard of care CAR T cell infusion in previously treated diffuse large b-cell
lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). The investigators
hypothesis is that this combination has the potential to significantly improve the ability of
CART cells to recognize and kill lymphoma cells without a significant impact on safety.
Participants will receive the tazemetostat pills before and after receiving their CAR T cell
therapy, for up to 12 months after CAR T cell administration. Patients will be followed for
up to 5 years.
Phase:
Phase 1
Details
Lead Sponsor:
Weill Medical College of Cornell University
Collaborators:
American Society of Clinical Oncology Applebaum Foundation Epizyme, Inc.